Literature DB >> 1646621

A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.

A D Bainbridge1, R J MacFadyen, K R Lees, J L Reid.   

Abstract

1. The possibility of an acute pharmacokinetic or pharmacodynamic interaction between the ACE inhibitor ramipril and the calcium antagonist felodipine was examined in 12 normotensive male volunteers. 2. Ramipril (5 mg) and felodipine ER (10 mg) were administered orally in a double-blind, randomised, placebo-controlled, Latin square design to fasting subjects. 3. There was no evidence of a pharmacokinetic interaction between agents. The concentration-time profiles remained unaltered by coadministration of both agents. 4. Plasma ACE inhibition by ramiprilat was unaffected by concurrent felodipine. The trend towards increased fractional sodium excretion after felodipine was not influenced by ramipril. Plasma renin activity, aldosterone and catecholamines remained unaltered. 5. Combination therapy produced a statistically significant fall in blood pressure supine and erect which was not evident with monotherapy. The reflex tachycardia associated with felodipine monotherapy was significantly attenuated by the coadministration of ramipril. 6. This study presents further evidence for the effective combination of ACE inhibitors and calcium antagonists to lower blood pressure. The reflex tachycardia associated with calcium antagonist therapy can be significantly reduced by coadministration with sustained antihypertensive effect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646621      PMCID: PMC1368381          DOI: 10.1111/j.1365-2125.1991.tb05503.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  21 in total

1.  Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril.

Authors:  K Sugimoto; Y Kumagai; T Tateishi; H Seguchi; A Ebihara
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

2.  Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.

Authors:  S Landahl; B Edgar; M Gabrielsson; M Larsson; B Lernfelt; P Lundborg; C G Regårdh
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

3.  Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity.

Authors:  J K McKenzie; J A Clements
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

4.  A placebo-controlled dose-response study of felodipine extended release in hypertensive patients.

Authors:  H Liedholm; A Melander
Journal:  J Cardiovasc Pharmacol       Date:  1989-07       Impact factor: 3.105

5.  A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite.

Authors:  H G Eckert; G Münscher; R Oekonomopulos; H Strecker; H Urbach; H Wissmann
Journal:  Arzneimittelforschung       Date:  1985

6.  Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.

Authors:  M Bellet; P Sassano; T Guyenne; P Corvol; J Menard
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

7.  Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses.

Authors:  B Edgar; C G Regårdh; P Lundborg; S Romare; G Nyberg; O Rönn
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627

8.  Evidence in humans for a postsynaptic interaction between noradrenaline and angiotensin II with regard to systolic but not diastolic blood pressure.

Authors:  A D Struthers; S Pai; P H Seidelin; W J Coutie; J J Morton
Journal:  J Hypertens       Date:  1987-12       Impact factor: 4.844

9.  Dose-dependent effects of felodipine on diuresis and natriuresis in healthy subjects.

Authors:  B Bengtsson-Hasselgren; B Edgar; O Rönn
Journal:  J Cardiovasc Pharmacol       Date:  1988-08       Impact factor: 3.105

10.  An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1987-12       Impact factor: 3.105

View more
  7 in total

Review 1.  Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

Authors:  Risto S Cvetković; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  ACE inhibitors. Drug interactions of clinical significance.

Authors:  C Mignat; T Unger
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

3.  The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol.

Authors:  J M van Griensven; M Seibert-Grafe; H C Schoemaker; M Frölich; A F Cohen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 5.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of ramipril.

Authors:  S Meisel; A Shamiss; T Rosenthal
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

7.  The antihypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension.

Authors:  A D Bainbridge; R J Macfadyen; S Stark; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-10       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.